Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Accumulated Expenses (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Accumulated Expenses for 16 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 15.04% to $7.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.5 million, a 15.04% decrease, with the full-year FY2024 number at $7.8 million, down 25.42% from a year prior.
  • Accumulated Expenses was $7.5 million for Q3 2025 at Xtant Medical Holdings, down from $10.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.6 million in Q2 2025 to a low of $3.0 million in Q3 2021.
  • A 5-year average of $6.4 million and a median of $6.3 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 50.5% in 2021, then surged 132.41% in 2023.
  • Xtant Medical Holdings' Accumulated Expenses stood at $4.3 million in 2021, then rose by 26.37% to $5.5 million in 2022, then skyrocketed by 89.57% to $10.4 million in 2023, then dropped by 25.42% to $7.8 million in 2024, then dropped by 3.01% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Accumulated Expenses are $7.5 million (Q3 2025), $10.6 million (Q2 2025), and $6.3 million (Q1 2025).